Vanda Pharmaceuticals Secures Orphan Drug Status in Japan for Imsidolimab—10-Year Market Exclusivity on the Horizon?
Market Chameleon (Wed, 27-May 7:52 AM)
NEREUS Launch Marks Major Breakthrough for Motion Sickness—First New Prescription Option in Over 40 Years
Market Chameleon (Mon, 4-May 8:13 AM)
